CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Modern Immunotherapy for Triple-Negative Breast Cancer

Modern Immunotherapy for...

Recent Developments in Cancer Immunotherapy

Recent Developments in Cancer...

Novel Immunotherapies To Redefine The Cancer Therapy Market

Novel Immunotherapies To Redefine The...

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Modern Immunotherapy for Triple-Negative Breast Cancer

Modern Immunotherapy for...

Recent Developments in Cancer Immunotherapy

Recent Developments in Cancer...

Novel Immunotherapies To Redefine The Cancer Therapy Market

Novel Immunotherapies To Redefine The...

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Types of Cancers that Immunotherapy May Help Cure

Life Sciences Review | Friday, April 01, 2022
Tweet

Immunotherapy is a relatively new form of precision medicine that assists the immune system in recognizing and combating cancer cells.


FREMONT, CA: Immunotherapy is a type of cancer treatment that enlists the assistance of own immune system in the fight against cancer. This is in contrast to conventional chemotherapy, which employs chemicals that kill cancerous and normal cells.


Each form of cancer is distinct. Immunotherapy is not effective against all types of cancer or in all patients with cancer. However, physicians continue to experiment with new medicines.


Specific forms of immunotherapy have become an integral part of the standard of care for certain types of cancer. Doctors may utilize it in the following ways:



  • Before pursuing other avenues of treatment

  • Whether alone or in conjunction with other forms of treatment such as chemotherapy

  • If alternative forms of treatment are ineffective, for example, in the case of malignancies that are resistant to treatment,


Bladder cancer is one of the cancers that immunotherapy can treat. There are now six FDA-approved treatment options for bladder cancer. They include the following:


Antibodies that are directed. This treatment disturbs cancer cells and signals the immune system to identify and eliminate them.


Immunotherapy against cancer


They aid the body in eradicating or stopping cancer cells and preventing their recurrence.


Modulators of the immune system that enhance the total immunological response. Inhibitors of checkpoints are one example.


Cancer of the brain. Several clinical studies are tested to determine whether immunotherapy can be used in situations when previous treatments have failed. There are two types of targeted antibodies approved to treat brain and nervous system malignancies.


Cancer of the breast. Initially, physicians believed immunotherapy was a poor treatment option for breast cancer. However, recent research indicates that particular women may benefit from it. Among these are women who produce an abnormal amount of a protein receptor called HER2. Numerous antibodies directed against the HER2 pathway are available. The FDA approved the first checkpoint inhibitor to treat breast cancer in 2019.


Cancer of the cervical cavity. Cervical cancer is treated with three cancer vaccines. Additionally, the FDA approved one checkpoint inhibitor and one monoclonal antibody, both forms of targeted therapy.


Cancer in children. Immunotherapy is approved for various forms of childhood cancer, including leukemia, lymphoma, and brain cancer. These include the following:



  • Antibodies with a specific target

  • Inhibitors of checkpoints

  • Adoptive cell treatment, such as CAR T-cell therapy, is a process in which T cells are genetically engineered to assist the immune system in locating and destroying cancer cells.


Colon cancer. This malignancy is treated with various targeted treatments, including checkpoint inhibitors. These may be more effective for patients who exhibit specific genetic characteristics.


Cancer of the esophagus. The FDA has approved two targeted treatments and one checkpoint inhibitor for this form of cancer. Researchers are examining the following strategies for launching immunotherapy against esophageal cancer:



  • Utilize it before undergoing other forms of treatment.

  • Combine it with other forms of therapy.

  • Attempt to keep it from reappearing.


Cancer of the head and neck. Immunotherapy may be especially beneficial for persons with head and neck malignancies caused by the human papillomavirus (HPV). Additionally, it may help avoid the severe side effects associated with other forms of treatment. The FDA has approved one targeted antibody and two checkpoint inhibitors for these tumors.


Cancer of the kidneys. This cancer is receiving a great deal of attention from researchers. Targeted treatments and cytokines were initially utilized to treat kidney cancer. Cytokines are proteins produced by white blood cells that stimulate the immune system to attack cancer cells. The FDA has also approved a monoclonal antibody and checkpoint inhibitors.


Weekly Brief

loading
Top 10 Cancer Immunotherapy Solutions Companies – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Antibodies: Immunoglobulin Isotypes

Life Science Consulting Services Trends

Rani Therapeutics and Celltrion Partner to Develop Oral Monoclonal Antibodies

ProPhase Labs Acquires BE-Smart Esophageal Pre-Cancer Screening Test

The Influence of Pharmaceutical Distributors on U.S. Drug Expenditures

Tips to Improve Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/-types-of-cancers-that-immunotherapy-may-help-cure-nwid-764.html